Trial register facet
Reported trial records — page 13
644 records with the status reported.
Showing 0 records on this page
Records
644 documents · page 13 of 27
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| ELAM-PH2-HFPEF-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Single-arm open-label | — | 2019 | Very low |
| PIONEER-6-REGIONAL-JPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-BIOMARKERprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-ADHERENCEprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Observational | — | 2019 | Very low |
| TESA-NAFLD-PH2-BODY-COMPprogramme record | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| SUSTAIN-7 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,201 | 2018 | High |
| AWARD-7 | Dulaglutide | Phase 3 | Reported | Randomised, open-label, active-controlled | 576 | 2018 | Low |
| HARMONY-OUTCOMES | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,463 | 2018 | Moderate |
| MMPOWER-2 | SS-31 (elamipretide) | Phase 2 | Reported | Randomised crossover | 30 | 2018 | Moderate |
| SUSTAIN-7-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-ELDERLYprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| AWARD-7-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Single-arm open-label | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2018 | Very low |
| AWARD-7-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Observational | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ELDERLYprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
page 13 of 27